This review explores how the neuromuscular junction (NMJ) develops from the neonatal period through childhood and how these developmental changes impact the pharmacology and clinical use of neuromuscular blocking agents (NMBAs).
At birth, the NMJ is functionally immature. Acetylcholine receptors are more widely distributed across the muscle membrane, including extrajunctional areas, and gradually concentrate at the motor endplate over the first months of life. Neuromuscular transmission is less efficient, and muscle fibers are smaller, contributing to differences in drug response compared to older children and adults.
These physiologic differences create a unique pharmacologic profile. Neonates and infants are more sensitive to nondepolarizing neuromuscular blockers at the receptor level. However, they also have a larger extracellular fluid volume, which increases the volume of distribution and can necessitate relatively higher weight-based dosing to achieve adequate blockade. The net effect is that dosing appears similar or slightly higher, but duration is often prolonged.
Succinylcholine has distinct considerations. Due to the larger extracellular fluid compartment, higher doses (around 2 mg/kg) are typically required for reliable intubating conditions. However, pediatric patients—especially those with undiagnosed myopathies—are at increased risk of life-threatening hyperkalemia and arrhythmias. Bradycardia is also more common, particularly with repeated dosing, often necessitating atropine pretreatment.
Onset and duration are influenced by developmental physiology. Neonates may have slower onset due to lower cardiac output and prolonged circulation time, while drug clearance is reduced because of immature hepatic and renal function. This leads to longer duration of action, particularly in preterm and very young infants.
Reversal of neuromuscular blockade requires careful consideration. Anticholinesterases are effective but must be dosed cautiously. Sugammadex provides rapid and reliable reversal of aminosteroid agents, but data in neonates and very young infants remain limited, and its routine use in this population is still evolving.
Monitoring is critical. Clinical assessment alone is unreliable in infants, and residual neuromuscular blockade may go undetected. Quantitative neuromuscular monitoring, when available, should be used to guide dosing and ensure adequate recovery.
Overall, the review reinforces that the interaction between NMJ development and NMBA pharmacology is complex and age-dependent, requiring thoughtful, individualized management.
Key Points
- Neonatal NMJ is immature with widespread acetylcholine receptors
- Increased sensitivity to nondepolarizing agents but larger volume of distribution
- Succinylcholine requires higher dosing but carries increased risk
- Slower onset and prolonged duration due to physiologic immaturity
- Immature organ function affects drug metabolism and clearance
- Objective neuromuscular monitoring is essential
What You Should Know
Pediatric neuromuscular blockade is not simply a scaled version of adult practice. The combination of increased receptor sensitivity and altered pharmacokinetics creates a narrow therapeutic window. The biggest risks are prolonged paralysis and unrecognized residual blockade. Careful dosing, avoidance of unnecessary redosing, and objective monitoring are critical to safe practice in neonates and infants.
We want to thank the European Journal of Anaesthesiology for allowing us to summarize and share this important work with the anesthesia community.